STANDARDS OF PROOF: A COMPARATIVE OVERVIEW FROM THE UKRAINIAN PERSPECTIVE



Enzyme replacement reduces neuropathology in MPS IIIA dogs

There read more is no treatment for the progressive neurodegenerative lysosomal storage disorder mucopolysaccharidosis type IIIA (MPS IIIA), which occurs due to a deficiency of functional N-sulfoglucosamine sulfohydrolase (SGSH), with subsequent accumulation of partially-degraded heparan sulfate and secondarily-stored compounds including GM2 and GM

read more